{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T14:22:18Z","timestamp":1794493338311,"version":"4.9.1"},"reference-count":171,"publisher":"Oxford University Press (OUP)","issue":"22","license":[{"start":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T00:00:00Z","timestamp":1609718400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB\/TRR 219"],"award-info":[{"award-number":["SFB\/TRR 219"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["322900939"],"award-info":[{"award-number":["322900939"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"European Uremic Toxin"},{"DOI":"10.13039\/501100016298","name":"ERA-EDTA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016298","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004362","name":"Swiss Heart Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004362","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chronic kidney disease (CKD) is associated with high cardiovascular risk. CKD patients exhibit a specific lipoprotein pattern termed \u2018uraemic dyslipidaemia\u2019, which is characterized by rather normal low-density lipoprotein cholesterol, low high-density lipoprotein cholesterol, and high triglyceride plasma levels. All three lipoprotein classes are involved in the pathogenesis of CKD-associated cardiovascular diseases (CVDs). Uraemia leads to several modifications of the structure of lipoproteins such as changes of the proteome and the lipidome, post-translational protein modifications (e.g. carbamylation) and accumulation of small-molecular substances within the lipoprotein moieties, which affect their functionality. Lipoproteins from CKD patients interfere with lipid transport and promote inflammation, oxidative stress, endothelial dysfunction as well as other features of atherogenesis, thus contributing to the development of CKD-associated CVD. While, lipid-modifying therapies play an important role in the management of CKD patients, their efficacy is modulated by kidney function. Novel therapeutic agents to prevent the adverse remodelling of lipoproteins in CKD and to improve their functional properties are highly desirable and partially under development.<\/jats:p>","DOI":"10.1093\/eurheartj\/ehaa1050","type":"journal-article","created":{"date-parts":[[2020,12,8]],"date-time":"2020-12-08T23:35:16Z","timestamp":1607470516000},"page":"2170-2185","source":"Crossref","is-referenced-by-count":66,"title":["Lipoproteins in chronic kidney disease: from bench to bedside"],"prefix":"10.1093","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2491-6393","authenticated-orcid":false,"given":"Thimoteus","family":"Speer","sequence":"first","affiliation":[{"name":"Translational Cardio-Renal Medicine , Saarland University, Kirrberger Strasse, Building 41, D-66421 Homburg\/Saar, Germany"},{"name":"Department of Internal Medicine IV, Saarland University Hospital, Nephrology and Hypertension , Kirrberger Strasse, Building 41, D-66421 Homburg\/Saar, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M","family":"Ridker","sequence":"additional","affiliation":[{"name":"Center for Cardiovascular Disease Prevention, Brigham and Women\u2019s Hospital, Harvard Medical School , 900 Commonwealth Avenue, Boston, MA 02215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold","family":"von Eckardstein","sequence":"additional","affiliation":[{"name":"Institute of Clinical Chemistry , University Hospital Zurich, R\u00e4mistrasse 100, CH-8091 Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan J","family":"Schunk","sequence":"additional","affiliation":[{"name":"Translational Cardio-Renal Medicine , Saarland University, Kirrberger Strasse, Building 41, D-66421 Homburg\/Saar, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danilo","family":"Fliser","sequence":"additional","affiliation":[{"name":"Translational Cardio-Renal Medicine , Saarland University, Kirrberger Strasse, Building 41, D-66421 Homburg\/Saar, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,1,4]]},"reference":[{"key":"2022102612134314800_ehaa1050-B1","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1093\/eurheartj\/ehw106","article-title":"2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)","volume":"37","author":"Piepoli","year":"2016","journal-title":"Eur Heart J"},{"key":"2022102612134314800_ehaa1050-B2","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0140-6736(13)60595-4","article-title":"Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention","volume":"382","author":"Gansevoort","year":"2013","journal-title":"Lancet"},{"key":"2022102612134314800_ehaa1050-B3","volume-title":"United States Renal Data System: National Institutes of Health","year":"2015"},{"key":"2022102612134314800_ehaa1050-B4","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/j.jacc.2019.08.1017","article-title":"Chronic kidney disease and coronary artery disease: JACC state-of-the-art review","volume":"74","author":"Sarnak","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2022102612134314800_ehaa1050-B5","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/S0140-6736(14)60384-6","article-title":"Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure","volume":"383","author":"Ortiz","year":"2014","journal-title":"Lancet"},{"key":"2022102612134314800_ehaa1050-B6","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/nrneph.2010.143","article-title":"Atherosclerosis in CKD: differences from the general population","volume":"6","author":"Drueke","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"2022102612134314800_ehaa1050-B7","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1093\/ndt\/gft080","article-title":"Uraemic dyslipidaemia revisited: role of high-density lipoprotein","volume":"28","author":"Speer","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"2022102612134314800_ehaa1050-B8","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nrneph.2017.155","article-title":"Dyslipidaemia in nephrotic syndrome: mechanisms and treatment","volume":"14","author":"Agrawal","year":"2018","journal-title":"Nat Rev Nephrol"},{"key":"2022102612134314800_ehaa1050-B9","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/ki.1990.114","article-title":"Effect of chronic renal failure on high-density lipoprotein kinetics","volume":"37","author":"Fuh","year":"1990","journal-title":"Kidney Int"},{"key":"2022102612134314800_ehaa1050-B10","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1093\/ndt\/gfp120","article-title":"Plasma phospholipid transfer protein, cholesteryl ester transfer protein and lecithin:cholesterol acyltransferase in end-stage renal disease (ESRD)","volume":"24","author":"Pahl","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"2022102612134314800_ehaa1050-B11","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1161\/ATVBAHA.112.300110","article-title":"Endothelial lipase activity predicts high-density lipoprotein catabolism in hemodialysis: novel phospholipase assay in postheparin human plasma","volume":"32","author":"Miksztowicz","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022102612134314800_ehaa1050-B12","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1038\/ki.1995.239","article-title":"Decreased clearance of low-density lipoprotein in uremic patients under dialysis treatment","volume":"47","author":"Horkko","year":"1995","journal-title":"Kidney Int"},{"key":"2022102612134314800_ehaa1050-B13","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/ki.1994.73","article-title":"Decreased clearance of low-density lipoprotein in patients with chronic renal failure","volume":"45","author":"Horkko","year":"1994","journal-title":"Kidney Int"},{"key":"2022102612134314800_ehaa1050-B14","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1093\/ndt\/gfp026","article-title":"Low-density lipoprotein clearance in patients with chronic renal failure","volume":"24","author":"Kastarinen","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"2022102612134314800_ehaa1050-B15","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1161\/01.ATV.0000188555.60475.c2","article-title":"Delayed in vivo catabolism of intermediate-density lipoprotein and low-density lipoprotein in hemodialysis patients as potential cause of premature atherosclerosis","volume":"25","author":"Ikewaki","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022102612134314800_ehaa1050-B16","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1194\/jlr.M055624","article-title":"Top-down lipidomics of low density lipoprotein reveal altered lipid profiles in advanced chronic kidney disease","volume":"56","author":"Reis","year":"2015","journal-title":"J Lipid Res"},{"key":"2022102612134314800_ehaa1050-B17","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1021\/acs.jproteome.6b00956","article-title":"Combined clinical phenotype and lipidomic analysis reveals the impact of chronic kidney disease on lipid metabolism","volume":"16","author":"Chen","year":"2017","journal-title":"J Proteome Res"},{"key":"2022102612134314800_ehaa1050-B18","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1016\/j.jacc.2014.09.042","article-title":"Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease","volume":"64","author":"Rosenson","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2022102612134314800_ehaa1050-B19","doi-asserted-by":"crossref","first-page":"33997","DOI":"10.1074\/jbc.M113.495366","article-title":"Apolipoproteins C-I and C-III inhibit lipoprotein lipase activity by displacement of the enzyme from lipid droplets","volume":"288","author":"Larsson","year":"2013","journal-title":"J Biol Chem"},{"key":"2022102612134314800_ehaa1050-B20","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3390\/jcdd5030039","article-title":"Angiopoietin-like 3 (ANGPTL3) and atherosclerosis: lipid and non-lipid related effects","volume":"5","author":"Lupo","year":"2018","journal-title":"J Cardiovasc Dev Dis"},{"key":"2022102612134314800_ehaa1050-B21","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.tem.2013.12.005","article-title":"Regulation of lipoprotein lipase by Angptl4","volume":"25","author":"Dijk","year":"2014","journal-title":"Trends Endocrinol Metab"},{"key":"2022102612134314800_ehaa1050-B22","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/ki.1996.192","article-title":"Increased lipase inhibition in uremia: identification of pre-beta-HDL as a major inhibitor in normal and uremic plasma","volume":"49","author":"Cheung","year":"1996","journal-title":"Kidney Int"},{"key":"2022102612134314800_ehaa1050-B23","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1194\/jlr.M011163","article-title":"Plasma apolipoprotein C-III metabolism in patients with chronic kidney disease","volume":"52","author":"Ooi","year":"2011","journal-title":"J Lipid Res"},{"key":"2022102612134314800_ehaa1050-B24","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/0026-0495(89)90093-0","article-title":"Serum apolipoprotein profile of hypertriglyceridemic patients with chronic renal failure on hemodialysis: a comparison with type IV hyperlipoproteinemic patients","volume":"38","author":"Averna","year":"1989","journal-title":"Metab Clin Exp"},{"key":"2022102612134314800_ehaa1050-B25","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.kint.2016.02.031","article-title":"Impaired postprandial lipemic response in chronic kidney disease","volume":"90","author":"Saland","year":"2016","journal-title":"Kidney Int"},{"key":"2022102612134314800_ehaa1050-B26","doi-asserted-by":"crossref","first-page":"F262","DOI":"10.1152\/ajprenal.00099.2005","article-title":"Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences","volume":"290","author":"Vaziri","year":"2006","journal-title":"Am J Physiol Renal Physiol"},{"key":"2022102612134314800_ehaa1050-B27","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1046\/j.1523-1755.1998.00786.x","article-title":"Role of secondary hyperparathyroidism in the genesis of hypertriglyceridemia and VLDL receptor deficiency in chronic renal failure","volume":"53","author":"Liang","year":"1998","journal-title":"Kidney Int"},{"key":"2022102612134314800_ehaa1050-B28","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1038\/ki.1997.242","article-title":"Acquired VLDL receptor deficiency in experimental nephrosis","volume":"51","author":"Liang","year":"1997","journal-title":"Kidney Int"},{"key":"2022102612134314800_ehaa1050-B29","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/ki.1997.129","article-title":"Down-regulation of VLDL receptor expression in chronic experimental renal failure","volume":"51","author":"Vaziri","year":"1997","journal-title":"Kidney Int"},{"key":"2022102612134314800_ehaa1050-B30","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1681\/ASN.2017070798","article-title":"HDL in CKD-the devil is in the detail","volume":"29","author":"Kronenberg","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"2022102612134314800_ehaa1050-B31","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2010111144","article-title":"Uremia alters HDL composition and function","volume":"22","author":"Holzer","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"2022102612134314800_ehaa1050-B32","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1681\/ASN.2011070668","article-title":"Serum amyloid A in uremic HDL promotes inflammation","volume":"23","author":"Weichhart","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"2022102612134314800_ehaa1050-B33","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/j.kint.2017.05.020","article-title":"Kidney function is associated with an altered protein composition of high-density lipoprotein","volume":"92","author":"Rubinow","year":"2017","journal-title":"Kidney Int"},{"key":"2022102612134314800_ehaa1050-B34","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1681\/ASN.2013111219","article-title":"Restoration of renal function does not correct impairment of uremic HDL properties","volume":"26","author":"Kopecky","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2022102612134314800_ehaa1050-B35","doi-asserted-by":"crossref","first-page":"224","DOI":"10.2215\/CJN.06560714","article-title":"Quantification of HDL proteins, cardiac events, and mortality in patients with type 2 diabetes on hemodialysis","volume":"10","author":"Kopecky","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022102612134314800_ehaa1050-B36","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/nm1637","article-title":"Protein carbamylation links inflammation, smoking, uremia and atherogenesis","volume":"13","author":"Wang","year":"2007","journal-title":"Nat Med"},{"key":"2022102612134314800_ehaa1050-B37","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1093\/eurheartj\/ehu111","article-title":"Carbamylated low-density lipoprotein induces endothelial dysfunction","volume":"35","author":"Speer","year":"2014","journal-title":"Eur Heart J"},{"key":"2022102612134314800_ehaa1050-B38","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1681\/ASN.2010040365","article-title":"Chronic uremia stimulates LDL carbamylation and atherosclerosis","volume":"21","author":"Apostolov","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"2022102612134314800_ehaa1050-B39","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa1001689","article-title":"Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis","volume":"364","author":"Khera","year":"2011","journal-title":"N Engl J Med"},{"key":"2022102612134314800_ehaa1050-B40","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1056\/NEJMoa1409065","article-title":"HDL cholesterol efflux capacity and incident cardiovascular events","volume":"371","author":"Rohatgi","year":"2014","journal-title":"N Engl J Med"},{"key":"2022102612134314800_ehaa1050-B41","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/j.jacc.2012.09.013","article-title":"Dysfunctional high-density lipoprotein in patients on chronic hemodialysis","volume":"60","author":"Yamamoto","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2022102612134314800_ehaa1050-B42","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.2215\/CJN.11321017","article-title":"Alteration of HDL protein composition with hemodialysis initiation","volume":"13","author":"Wang","year":"2018","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022102612134314800_ehaa1050-B43","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1681\/ASN.2014030309","article-title":"Dialysis modalities and HDL composition and function","volume":"26","author":"Holzer","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2022102612134314800_ehaa1050-B44","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.jacc.2018.05.043","article-title":"Impaired renal function on cholesterol efflux capacity, HDL particle number, and cardiovascular events","volume":"72","author":"Chindhy","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2022102612134314800_ehaa1050-B45","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1681\/ASN.2014090857","article-title":"HDL cholesterol efflux predicts graft failure in renal transplant recipients","volume":"27","author":"Annema","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"2022102612134314800_ehaa1050-B46","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1681\/ASN.2013111212","article-title":"HDL in children with CKD promotes endothelial dysfunction and an abnormal vascular phenotype","volume":"25","author":"Shroff","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"2022102612134314800_ehaa1050-B47","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.yjmcc.2017.05.001","article-title":"Plasma metabolite profiles, cellular cholesterol efflux, and non-traditional cardiovascular risk in patients with CKD","volume":"112","author":"Ganda","year":"2017","journal-title":"J Mol Cell Cardiol"},{"key":"2022102612134314800_ehaa1050-B48","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1161\/ATVBAHA.114.304172","article-title":"Lower Apo A-I and lower HDL-C levels are associated with higher intermediate CD14++CD16+ monocyte counts that predict cardiovascular events in chronic kidney disease","volume":"34","author":"Rogacev","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022102612134314800_ehaa1050-B49","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1161\/CIRCULATIONAHA.117.032636","article-title":"Cholesterol efflux pathways suppress inflammasome activation, NETosis, and atherogenesis","volume":"138","author":"Westerterp","year":"2018","journal-title":"Circulation"},{"key":"2022102612134314800_ehaa1050-B50","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.immuni.2013.02.009","article-title":"Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2","volume":"38","author":"Speer","year":"2013","journal-title":"Immunity"},{"key":"2022102612134314800_ehaa1050-B51","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1093\/eurheartj\/ehx118","article-title":"Symmetric dimethylarginine, high-density lipoproteins and cardiovascular disease","volume":"38","author":"Zewinger","year":"2017","journal-title":"Eur Heart J"},{"key":"2022102612134314800_ehaa1050-B52","first-page":"3007","article-title":"Serum amyloid A: high-density lipoproteins interaction and cardiovascular risk","volume":"36","author":"Zewinger","year":"2015","journal-title":"Eur Heart J"},{"key":"2022102612134314800_ehaa1050-B53","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/j.1523-1755.2005.00391.x","article-title":"Carbamylated low-density lipoprotein induces death of endothelial cells: a link to atherosclerosis in patients with kidney disease","volume":"68","author":"Ok","year":"2005","journal-title":"Kidney Int"},{"key":"2022102612134314800_ehaa1050-B54","doi-asserted-by":"crossref","first-page":"e0165576","DOI":"10.1371\/journal.pone.0165576","article-title":"Carbamylated low-density lipoprotein (cLDL)-mediated induction of autophagy and its role in endothelial cell injury","volume":"11","author":"Bose","year":"2016","journal-title":"PLoS One"},{"key":"2022102612134314800_ehaa1050-B55","doi-asserted-by":"crossref","first-page":"F511","DOI":"10.1152\/ajprenal.00508.2015","article-title":"Increased carbamylation level of HDL in end-stage renal disease: carbamylated-HDL attenuated endothelial cell function","volume":"310","author":"Sun","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"key":"2022102612134314800_ehaa1050-B56","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nri3452","article-title":"Activation and regulation of the inflammasomes","volume":"13","author":"Latz","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"2022102612134314800_ehaa1050-B57","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/nature08938","article-title":"NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals","volume":"464","author":"Duewell","year":"2010","journal-title":"Nature"},{"key":"2022102612134314800_ehaa1050-B58","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/ni.2639","article-title":"CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation","volume":"14","author":"Sheedy","year":"2013","journal-title":"Nat Immunol"},{"key":"2022102612134314800_ehaa1050-B59","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41590-019-0548-1","article-title":"Apolipoprotein C3 induces inflammation and organ damage by alternative inflammasome activation","volume":"21","author":"Zewinger","year":"2020","journal-title":"Nat Immunol"},{"key":"2022102612134314800_ehaa1050-B60","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1681\/ASN.2019111205","article-title":"CKD increases carbonylation of HDL and is associated with impaired antiaggregant properties","volume":"31","author":"Florens","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"2022102612134314800_ehaa1050-B61","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.jacc.2016.07.755","article-title":"Carbamylated low-density lipoproteins induce a prothrombotic state via LOX-1: impact on arterial thrombus formation in vivo","volume":"68","author":"Holy","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2022102612134314800_ehaa1050-B62","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1373\/clinchem.2009.142810","article-title":"Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures","volume":"56","author":"Miller","year":"2010","journal-title":"Clin Chem"},{"key":"2022102612134314800_ehaa1050-B63","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1001\/archinte.164.8.863","article-title":"Seasonal variation in serum cholesterol levels: treatment implications and possible mechanisms","volume":"164","author":"Ockene","year":"2004","journal-title":"Arch Intern Med"},{"key":"2022102612134314800_ehaa1050-B64","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"2022102612134314800_ehaa1050-B65","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"key":"2022102612134314800_ehaa1050-B66","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1056\/NEJMoa1604304","article-title":"Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes","volume":"375","author":"Ference","year":"2016","journal-title":"N Engl J Med"},{"key":"2022102612134314800_ehaa1050-B67","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1016\/j.jacc.2015.02.020","article-title":"Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 x 2 factorial Mendelian randomization study","volume":"65","author":"Ference","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2022102612134314800_ehaa1050-B68","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1681\/ASN.2012080870","article-title":"Association between LDL-C and risk of myocardial infarction in CKD","volume":"24","author":"Tonelli","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"2022102612134314800_ehaa1050-B69","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1053\/j.ajkd.2009.06.029","article-title":"Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus","volume":"54","author":"Krane","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"2022102612134314800_ehaa1050-B70","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/hrt.2009.184879","article-title":"Arterial stiffness in chronic kidney disease: causes and consequences","volume":"96","author":"Chue","year":"2010","journal-title":"Heart"},{"key":"2022102612134314800_ehaa1050-B71","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/heartjnl-2012-302818","article-title":"Arterial disease in chronic kidney disease","volume":"99","author":"Moody","year":"2013","journal-title":"Heart"},{"key":"2022102612134314800_ehaa1050-B72","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.jcmg.2013.09.025","article-title":"Defining the natural history of uremic cardiomyopathy in chronic kidney disease: the role of cardiovascular magnetic resonance","volume":"7","author":"Edwards","year":"2014","journal-title":"JACC Cardiovasc Imaging"},{"key":"2022102612134314800_ehaa1050-B73","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1681\/ASN.2013090965","article-title":"Effects of lowering LDL cholesterol on progression of kidney disease","volume":"25","author":"Haynes","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"2022102612134314800_ehaa1050-B74","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1681\/ASN.2006070795","article-title":"Association between serum lipids and survival in hemodialysis patients and impact of race","volume":"18","author":"Kilpatrick","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"2022102612134314800_ehaa1050-B75","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1001\/jama.291.4.451","article-title":"Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition","volume":"291","author":"Liu","year":"2004","journal-title":"JAMA"},{"key":"2022102612134314800_ehaa1050-B76","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1194\/jlr.R071233","article-title":"Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology","volume":"57","author":"Nordestgaard","year":"2016","journal-title":"J Lipid Res"},{"key":"2022102612134314800_ehaa1050-B77","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1093\/eurheartj\/ehx033","article-title":"Lipoprotein(a): the revenant","volume":"38","author":"Gencer","year":"2017","journal-title":"Eur Heart J"},{"key":"2022102612134314800_ehaa1050-B78","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2022102612134314800_ehaa1050-B79","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.jacc.2017.01.017","article-title":"Lipoprotein(a) improves cardiovascular risk prediction based on established risk algorithms","volume":"69","author":"Verbeek","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2022102612134314800_ehaa1050-B80","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11789-019-00101-8","article-title":"Is lipoprotein(a) a risk factor for ischemic stroke and venous thromboembolism?","volume":"14","author":"Nave","year":"2019","journal-title":"Clin Res Cardiol Suppl"},{"key":"2022102612134314800_ehaa1050-B81","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12944-019-1092-6","article-title":"Prognostic value of lipoprotein (a) level in patients with coronary artery disease: a meta-analysis","volume":"18","author":"Wang","year":"2019","journal-title":"Lipids Health Dis"},{"key":"2022102612134314800_ehaa1050-B82","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1038\/s41569-018-0153-2","article-title":"Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease","volume":"16","author":"Boffa","year":"2019","journal-title":"Nat Rev Cardiol"},{"key":"2022102612134314800_ehaa1050-B83","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S2213-8587(17)30096-7","article-title":"Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: a molecular and genetic association study","volume":"5","author":"Zewinger","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022102612134314800_ehaa1050-B84","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1194\/jlr.R083626","article-title":"The role of lipoprotein (a) in chronic kidney disease","volume":"59","author":"Hopewell","year":"2018","journal-title":"J Lipid Res"},{"key":"2022102612134314800_ehaa1050-B85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1194\/jlr.R071571","article-title":"Lipoprotein (a): a historical appraisal","volume":"58","author":"Kostner","year":"2017","journal-title":"J Lipid Res"},{"key":"2022102612134314800_ehaa1050-B86","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1021\/ja00430a023","article-title":"Labilization of 3-carbon hydrogens in chelated (2S)-aspartic acid and erythro- and threo-(2S)-3-methylaspartic acid","volume":"98","author":"McClarin","year":"1976","journal-title":"J Am Chem Soc"},{"key":"2022102612134314800_ehaa1050-B87","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1161\/ATVBAHA.117.309920","article-title":"Lipoprotein(a) and risk of myocardial infarction and death in chronic kidney disease: findings from the CRIC study (Chronic Renal Insufficiency Cohort)","volume":"37","author":"Bajaj","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022102612134314800_ehaa1050-B88","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1093\/ndt\/gfv428","article-title":"Lipoprotein(a) concentrations, apolipoprotein(a) isoforms and clinical endpoints in haemodialysis patients with type 2 diabetes mellitus: results from the 4D Study","volume":"31","author":"Kollerits","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"2022102612134314800_ehaa1050-B89","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1161\/01.CIR.97.11.1029","article-title":"Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study","volume":"97","author":"Jeppesen","year":"1998","journal-title":"Circulation"},{"key":"2022102612134314800_ehaa1050-B90","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jacc.2017.12.006","article-title":"Lipids, lipoproteins, and metabolites and risk of myocardial infarction and stroke","volume":"71","author":"Holmes","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2022102612134314800_ehaa1050-B91","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jacc.2007.10.038","article-title":"Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial","volume":"51","author":"Miller","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2022102612134314800_ehaa1050-B92","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/ng.2795","article-title":"Common variants associated with plasma triglycerides and risk for coronary artery disease","volume":"45","author":"Do","year":"2013","journal-title":"Nat Genet"},{"key":"2022102612134314800_ehaa1050-B93","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1126\/science.1161524","article-title":"A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection","volume":"322","author":"Pollin","year":"2008","journal-title":"Science"},{"key":"2022102612134314800_ehaa1050-B94","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1308027","article-title":"Loss-of-function mutations in APOC3 and risk of ischemic vascular disease","volume":"371","author":"J\u00f8rgensen","year":"2014","journal-title":"N Engl J Med"},{"key":"2022102612134314800_ehaa1050-B95","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1612790","article-title":"Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease","volume":"377","author":"Dewey","year":"2017","journal-title":"N Engl J Med"},{"key":"2022102612134314800_ehaa1050-B96","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1056\/NEJMoa1510926","article-title":"Inactivating variants in ANGPTL4 and risk of coronary artery disease","volume":"374","author":"Dewey","year":"2016","journal-title":"N Engl J Med"},{"key":"2022102612134314800_ehaa1050-B97","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1002926","article-title":"Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia","volume":"363","author":"Musunuru","year":"2010","journal-title":"N Engl J Med"},{"key":"2022102612134314800_ehaa1050-B98","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1053\/j.ajkd.2018.11.010","article-title":"Lipids, apolipoproteins, and risk of atherosclerotic cardiovascular disease in persons with CKD","volume":"73","author":"Bajaj","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"2022102612134314800_ehaa1050-B99","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2215\/CJN.07320619","article-title":"Apolipoprotein B, triglyceride-rich lipoproteins, and risk of cardiovascular events in persons with CKD","volume":"15","author":"Lamprea-Montealegre","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022102612134314800_ehaa1050-B100","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.2215\/CJN.01450210","article-title":"Hyperlipidemia and long-term outcomes in nondiabetic chronic kidney disease","volume":"5","author":"Chawla","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022102612134314800_ehaa1050-B101","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1053\/j.ajkd.2015.05.011","article-title":"Impact of the triglycerides to high-density lipoprotein cholesterol ratio on the incidence and progression of CKD: a longitudinal study in a Large Japanese Population","volume":"66","author":"Tsuruya","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"2022102612134314800_ehaa1050-B102","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2215\/CJN.09320913","article-title":"Relation of serum lipids and lipoproteins with progression of CKD: the CRIC study","volume":"9","author":"Rahman","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022102612134314800_ehaa1050-B103","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1053\/j.ajkd.2017.06.011","article-title":"HDL cholesterol, LDL cholesterol, and triglycerides as risk factors for CKD: a Mendelian Randomization Study","volume":"71","author":"Lanktree","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"2022102612134314800_ehaa1050-B104","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2009.1619","article-title":"Major lipids, apolipoproteins, and risk of vascular disease","volume":"302","author":"Di Angelantonio","year":"2009","journal-title":"JAMA"},{"key":"2022102612134314800_ehaa1050-B105","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrcardio.2017.115","article-title":"HDL and atherosclerotic cardiovascular disease: genetic insights into complex biology","volume":"15","author":"Rosenson","year":"2018","journal-title":"Nat Rev Cardiol"},{"key":"2022102612134314800_ehaa1050-B106","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","article-title":"Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study","volume":"380","author":"Voight","year":"2012","journal-title":"Lancet"},{"key":"2022102612134314800_ehaa1050-B107","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1681\/ASN.2013050482","article-title":"HDL cholesterol is not associated with lower mortality in patients with kidney dysfunction","volume":"25","author":"Zewinger","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"2022102612134314800_ehaa1050-B108","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1681\/ASN.2013080816","article-title":"HDL cholesterol, apolipoproteins, and cardiovascular risk in hemodialysis patients","volume":"26","author":"Silbernagel","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2022102612134314800_ehaa1050-B109","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/ndt\/gfu022","article-title":"Elevated high-density lipoprotein cholesterol and cardiovascular mortality in maintenance hemodialysis patients","volume":"29","author":"Moradi","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"2022102612134314800_ehaa1050-B110","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.2215\/CJN.00730116","article-title":"High density lipoprotein cholesterol and the risk of all-cause mortality among U.S. Veterans","volume":"11","author":"Bowe","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022102612134314800_ehaa1050-B111","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"2022102612134314800_ehaa1050-B112","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators","volume":"335","author":"Sacks","year":"1996","journal-title":"N Engl J Med"},{"key":"2022102612134314800_ehaa1050-B113","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"2022102612134314800_ehaa1050-B114","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/S0140-6736(03)13636-7","article-title":"MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial","volume":"361","author":"Collins","year":"2003","journal-title":"Lancet"},{"key":"2022102612134314800_ehaa1050-B115","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"2022102612134314800_ehaa1050-B116","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1161\/01.CIR.0000143892.84582.60","article-title":"Effect of pravastatin on cardiovascular events in people with chronic kidney disease","volume":"110","author":"Tonelli","year":"2004","journal-title":"Circulation"},{"key":"2022102612134314800_ehaa1050-B117","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"2022102612134314800_ehaa1050-B118","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.jacc.2007.11.072","article-title":"Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study","volume":"51","author":"Shepherd","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"2022102612134314800_ehaa1050-B119","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N Engl J Med"},{"key":"2022102612134314800_ehaa1050-B120","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Fellstrom","year":"2009","journal-title":"N Engl J Med"},{"key":"2022102612134314800_ehaa1050-B121","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a Randomised Placebo-Controlled Trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"2022102612134314800_ehaa1050-B122","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S2213-8587(16)30156-5","article-title":"Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials","volume":"4","author":"Herrington","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2022102612134314800_ehaa1050-B123","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1016\/j.jacc.2015.03.551","article-title":"Intestinal cholesterol absorption, treatment with atorvastatin, and cardiovascular risk in hemodialysis patients","volume":"65","author":"Silbernagel","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2022102612134314800_ehaa1050-B124","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0140-6736(18)31942-1","article-title":"Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials","volume":"393","year":"2019","journal-title":"Lancet"},{"key":"2022102612134314800_ehaa1050-B125","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1111\/j.1600-6143.2005.01105.x","article-title":"Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study","volume":"5","author":"Holdaas","year":"2005","journal-title":"Am J Transplant"},{"key":"2022102612134314800_ehaa1050-B126","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1093\/ndt\/gfy151","article-title":"Metabolic risk profile in kidney transplant candidates and recipients","volume":"34","author":"Piotti","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"2022102612134314800_ehaa1050-B127","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1053\/j.ajkd.2016.01.016","article-title":"Effect of statins on kidney disease outcomes: a systematic review and meta-analysis","volume":"67","author":"Su","year":"2016","journal-title":"Am J Kidney Dis"},{"key":"2022102612134314800_ehaa1050-B128","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1016\/j.jacc.2019.07.037","article-title":"Impact of LDL cholesterol on microvascular versus macrovascular disease: a Mendelian Randomization Study","volume":"74","author":"Emanuelsson","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2022102612134314800_ehaa1050-B129","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy\u2013a genomewide study","volume":"359","author":"Link","year":"2008","journal-title":"N Engl J Med"},{"key":"2022102612134314800_ehaa1050-B130","doi-asserted-by":"crossref","first-page":"263","DOI":"10.7326\/0003-4819-157-4-201208210-00007","article-title":"Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis","volume":"157","author":"Palmer","year":"2012","journal-title":"Ann Intern Med"},{"key":"2022102612134314800_ehaa1050-B131","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/j.amjcard.2014.03.046","article-title":"Statin and the risk of renal-related serious adverse events: Analysis from the IDEAL, TNT, CARDS, ASPEN, SPARCL, and other placebo-controlled trials","volume":"113","author":"Bangalore","year":"2014","journal-title":"Am J Cardiol"},{"key":"2022102612134314800_ehaa1050-B132","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"2022102612134314800_ehaa1050-B133","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"2022102612134314800_ehaa1050-B134","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1093\/ndt\/gfz122","article-title":"Proprotein convertase subtilisin\/kexin type 9 in kidney disease","volume":"34","author":"Schmit","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"2022102612134314800_ehaa1050-B135","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.kint.2017.12.011","article-title":"Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease","volume":"93","author":"Toth","year":"2018","journal-title":"Kidney Int"},{"key":"2022102612134314800_ehaa1050-B136","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1016\/j.jacc.2019.03.513","article-title":"Efficacy and safety of evolocumab in chronic kidney disease in the FOURIER trial","volume":"73","author":"Charytan","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2022102612134314800_ehaa1050-B137","doi-asserted-by":"crossref","first-page":"182","DOI":"10.2215\/CJN.00740805","article-title":"Review of the effects of omega-3 supplementation in dialysis patients","volume":"1","author":"Friedman","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022102612134314800_ehaa1050-B138","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1093\/ndt\/gfn180","article-title":"The effect of n-3 fatty acids on lipids and lipoproteins in patients treated with chronic haemodialysis: a randomized placebo-controlled intervention study","volume":"23","author":"Svensson","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"2022102612134314800_ehaa1050-B139","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.3109\/0886022X.2010.510231","article-title":"Effects of omega-3 on lipid profile and inflammation markers in peritoneal dialysis patients","volume":"32","author":"Hassan","year":"2010","journal-title":"Ren Fail"},{"key":"2022102612134314800_ehaa1050-B140","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3810\/pgm.2014.11.2828","article-title":"Overview of prescription omega-3 fatty acid products for hypertriglyceridemia","volume":"126","author":"Weintraub","year":"2014","journal-title":"Postgrad Med"},{"key":"2022102612134314800_ehaa1050-B141","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.amjcard.2012.05.031","article-title":"Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study)","volume":"110","author":"Ballantyne","year":"2012","journal-title":"Am J Cardiol"},{"key":"2022102612134314800_ehaa1050-B142","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jacl.2013.10.003","article-title":"Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial","volume":"8","author":"Kastelein","year":"2014","journal-title":"J Clin Lipidol"},{"key":"2022102612134314800_ehaa1050-B143","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/s11883-011-0210-3","article-title":"Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis","volume":"13","author":"Wei","year":"2011","journal-title":"Curr Atheroscler Rep"},{"key":"2022102612134314800_ehaa1050-B144","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"2022102612134314800_ehaa1050-B145","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1001\/jama.2019.17380","article-title":"Effect of vitamin D and omega-3 fatty acid supplementation on kidney function in patients with type 2 diabetes: a randomized clinical trial","volume":"322","author":"de Boer","year":"2019","journal-title":"JAMA"},{"key":"2022102612134314800_ehaa1050-B146","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"key":"2022102612134314800_ehaa1050-B147","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1001\/jama.285.12.1585","article-title":"Veterans Affairs High-Density Lipoprotein Intervention Trial. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial","volume":"285","author":"Robins","year":"2001","journal-title":"JAMA"},{"key":"2022102612134314800_ehaa1050-B148","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"2022102612134314800_ehaa1050-B149","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"key":"2022102612134314800_ehaa1050-B150","first-page":"94"},{"key":"2022102612134314800_ehaa1050-B151","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1093\/ndt\/16.7.1515","article-title":"Fibrate-induced increase in blood urea and creatinine","volume":"16","author":"Lipscombe","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"2022102612134314800_ehaa1050-B152","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1007\/s11883-009-0051-5","article-title":"Fibrate therapy and renal function","volume":"11","author":"Sica","year":"2009","journal-title":"Curr Atheroscler Rep"},{"key":"2022102612134314800_ehaa1050-B153","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ahj.2018.09.011","article-title":"Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study","volume":"206","author":"Pradhan","year":"2018","journal-title":"Am Heart J"},{"key":"2022102612134314800_ehaa1050-B154","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1159\/000505365","article-title":"Cholesteryl ester transfer protein inhibitors and cardiovascular outcomes: a systematic review and meta-analysis of randomized controlled trials","volume":"145","author":"Taheri","year":"2020","journal-title":"Cardiology"},{"key":"2022102612134314800_ehaa1050-B155","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s10557-019-06865-1","article-title":"HDL-targeted therapies during myocardial infarction","volume":"33","author":"Sposito","year":"2019","journal-title":"Cardiovasc Drugs Ther"},{"key":"2022102612134314800_ehaa1050-B156","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1194\/jlr.R056549","article-title":"Lipoprotein apheresis to treat elevated lipoprotein (a)","volume":"57","author":"Waldmann","year":"2016","journal-title":"J Lipid Res"},{"key":"2022102612134314800_ehaa1050-B157","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1161\/ATVBAHA.116.307983","article-title":"Lipoprotein apheresis for lipoprotein(a)-associated cardiovascular disease: prospective 5 years of follow-up and apolipoprotein(a) characterization","volume":"36","author":"Roeseler","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022102612134314800_ehaa1050-B158","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1194\/jlr.R053066","article-title":"Current therapies for lowering lipoprotein (a)","volume":"57","author":"van Capelleveen","year":"2016","journal-title":"J Lipid Res"},{"key":"2022102612134314800_ehaa1050-B159","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jacc.2020.05.070","article-title":"Targeting RNA with antisense oligonucleotides and small interfering RNA: JACC State-of-the-Art Review","volume":"76","author":"Katzmann","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"2022102612134314800_ehaa1050-B160","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","article-title":"Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials","volume":"388","author":"Viney","year":"2016","journal-title":"Lancet"},{"key":"2022102612134314800_ehaa1050-B161","article-title":"Targeting cardiovascular inflammation: next steps in clinical translation","author":"Lawler","year":"2020","journal-title":"Eur Heart J"},{"key":"2022102612134314800_ehaa1050-B162","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1161\/CIRCULATIONAHA.118.034645","article-title":"Residual inflammatory risk on treatment with PCSK9 inhibition and statin therapy","volume":"138","author":"Pradhan","year":"2018","journal-title":"Circulation"},{"key":"2022102612134314800_ehaa1050-B163","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1093\/eurheartj\/ehaa160","article-title":"Comparison of interleukin-6, C-reactive protein, and low-density lipoprotein cholesterol as biomarkers of residual risk in contemporary practice: secondary analyses from the Cardiovascular Inflammation Reduction Trial","volume":"41","author":"Ridker","year":"2020","journal-title":"Eur Heart J"},{"key":"2022102612134314800_ehaa1050-B164","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1053\/j.ajkd.2018.09.012","article-title":"Use of measures of inflammation and kidney function for prediction of atherosclerotic vascular disease events and death in patients with CKD: findings from the CRIC Study","volume":"73","author":"Amdur","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"2022102612134314800_ehaa1050-B165","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.kint.2016.10.021","article-title":"Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease","volume":"91","author":"Munoz Mendoza","year":"2017","journal-title":"Kidney Int"},{"key":"2022102612134314800_ehaa1050-B166","doi-asserted-by":"crossref","first-page":"702","DOI":"10.2215\/CJN.04360418","article-title":"IL-1 inhibition and function of the HDL-containing fraction of plasma in patients with stages 3 to 5 CKD","volume":"14","author":"Hung","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022102612134314800_ehaa1050-B167","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"2022102612134314800_ehaa1050-B168","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"key":"2022102612134314800_ehaa1050-B169","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1016\/j.jacc.2018.03.490","article-title":"Inhibition of interleukin-1beta by canakinumab and cardiovascular outcomes in patients with chronic kidney disease","volume":"71","author":"Ridker","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2022102612134314800_ehaa1050-B170","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"key":"2022102612134314800_ehaa1050-B171","article-title":"Cardiac imaging for coronary heart disease risk stratification in chronic kidney disease","author":"Dilsizian","year":"2020","journal-title":"JACC Cardiovasc Imaging"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/42\/22\/2170\/46643843\/ehaa1050.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/42\/22\/2170\/46643843\/ehaa1050.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,26]],"date-time":"2022-10-26T08:16:27Z","timestamp":1666772187000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/42\/22\/2170\/6062268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,4]]},"references-count":171,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2021,1,4]]},"published-print":{"date-parts":[[2021,6,7]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehaa1050","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,6,7]]},"published":{"date-parts":[[2021,1,4]]}}}